arrow
T

Takeru Wakatsuki

Department of Gastroenterological Chemotherapy
H指数:24
被引数:2,541

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study

日本接受 fruquintinib 治疗的转移性结直肠癌患者中,蛋白尿作为早期剂量调整的原因:一项多中心真实世界研究

2026-08-270
OAAI
Usefulness of pharmacy outpatient clinic follow-up for maintaining relative dose intensity in patients on adjuvant CAPOX chemotherapy for gastric cancer

胃癌辅助CAPOX化疗患者中药房门诊随访对维持相对剂量强度的作用

2026-05-010
PRE
Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023

HER2阳性晚期胃癌患者真实世界中的治疗选择增加和生存改善(2011年至2023年)

2026-04-110
PRE
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab deruxtecan efficacy in patients with HER2-positive gastric cancer

HER2阳性胃癌患者中肿瘤内HER2异质性对曲妥珠单抗德鲁替康疗效的临床影响

2026-04-020
OAAI
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer

基于拷贝数分析的癌基因主导性可能提示ERBB2依赖性及曲妥珠单抗应答在HER2阳性胃癌中的情况

2026-03-150
OAAI
Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience

Zolbetuximab联合化疗在Claudin 18亚型2阳性晚期胃癌中的安全性与有效性:真实世界经验的初步报告

2025-12-180
OAAI
Glucocorticoids rarely required in granulocyte colony-stimulating factor-associated large-vessel vasculitis: Japanese cancer centre cohort

糖皮质激素在粒细胞集落刺激因子相关大血管血管炎中很少需要:日本癌症中心队列

2025-12-010
PRE
Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

早期较高的血浆瑞戈菲布浓度预示日本结直肠癌患者无进展生存期缩短

2025-11-040
OAAI
Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High)

循环肿瘤DNA在HER2阳性晚期胃癌中的临床意义:一项关于HER2和PD-1双靶向疗法(Ni-High)的 Ib 期临床试验的协作研究

2025-09-120
OA
Effect of pretreatment vascular endothelial growth factor inhibitor use on the safety and efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

使用术前血管内皮生长因子抑制剂的既往用药对三氟尿idine/替吡拉塞联合贝伐珠单抗在转移性结直肠癌患者中安全性与有效性的影响

2025-07-210
PRE
Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors

自动化和去中心化的血浆游离DNA基因组分析,用于识别晚期实体瘤中的可靶向突变和耐药性改变

2025-05-050
OA
Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings

早期肿瘤缩小对接受曲妥珠单抗德鲁替康治疗的三线或更后线治疗的HER2阳性晚期胃癌患者生存结局的影响

2025-04-240
OA
Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma

多西他赛、顺铂和5-氟尿嘧啶新辅助治疗局部晚期食管鳞状细胞癌的真实世界安全性和有效性

2025-04-080
OAAI
Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023

调查2011年至2023年间免疫疗法在HER2阴性晚期胃癌真实世界患者中的作用

2025-02-240
OA